93509-70-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Isoxazolamine,5-(2-methoxy-1,1-dimethylethyl)-(9CI) is used as a drug intermediate for the synthesis of various pharmaceutical products due to its unique chemical structure and biological activities.
Used in Agricultural Industry:
3-Isoxazolamine,5-(2-methoxy-1,1-dimethylethyl)-(9CI) is used as an insecticide and fungicide in agriculture, providing effective control of pests and diseases in crops.
Used in Organic Synthesis:
3-Isoxazolamine,5-(2-methoxy-1,1-dimethylethyl)-(9CI) is used as a building block in organic synthesis for the preparation of various complex molecules, contributing to the development of new chemical compounds and materials.

Upstream product

• 25307-88-4 methyl 3-methoxy-2,2-dimethylpropionate 
• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 
• 90087-79-9 5-methoxy-4,4-dimethyl-3-oxopentanenitrile 

Downstream Products

• 1188908-71-5 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-methoxy-2-methylpropan-2-yl)isoxazol-3-yl)urea 

Relevant academic research and scientific papers

SULPHONAMIDE COMPOUNDS

This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E

The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID.

Compounds Which Selectively Modulate The CB2 Receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu

HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.